But is that not the main reason for doing a Phase 1 trial being to treat at varying dosage rates to see at what level is acceptable both for healing and for toxicity ?
However there was some research done by Collins et al that dosage rate should not be the main indicator as important to also look at the "probability" of a particular dosage rate being at an acceptable level of toxicity. http://brb.nci.nih.gov/techreport/phaseIctd.pdf
NRT Price at posting:
30.5¢ Sentiment: Buy Disclosure: Held
